The study's objective was to develop a matrix tablet formulation of Gliclazide. The new formulation will provide the benefit of SR formulations of gliclazide, an anti-diabetic medication that stimulates insulin production through the beta cell sulfonylurea receptor. Matrix tablets containing Gliclazide were made using the wet granulation technique, and their drug release characteristics were studied. Natural polymers like pectin were used into the formulation. Polymers in pectin are hydrophilic and can slow or speed things up. There was evidence that all of the formulations met pharmacopeial requirements. There are six distinct formulations, each with a unique drug:polymer concentration. HPMC K100M-F1 (1:1), F2 (1:2), F3 (1:3), F4 (1:1), F5 (1:2), and F6 (1:3) all include the medicine in a polysaccharide form of pectin, while the remaining three formulations all have the drug in a polymer combination of pectin. After 12 hours, F6 is the only formulation that exhibits any sign of sustained release. The optimized formulation F6 containing (pectin and HPMC K100M) is superior to other formulations in terms of sustained efficacy over a 12-hour period. Increasing the polymer concentration resulted in a noticeable change in the drug's release kinetics. To assess the mechanism of drug release, the data was fitted to several (mathematical) models, including the higuchi, first-order, and zero-order. The best formulation, f6, is governed by zero-order kinetics